Text Size
12548 studies found for:    Open Studies | "Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Esophageal Cancer;   Head and Neck Cancer;   Lung Cancer
Interventions: Other: 18F-fluoromisonidazole;   Other: fluorescence angiography;   Other: laboratory biomarker analysis;   Procedure: infrared thermography;   Procedure: magnetic resonance imaging;   Procedure: therapeutic conventional surgery;   Radiation: [18F]-ML-10;   Radiation: fludeoxyglucose F 18;   Radiation: rubidium Rb-82
2 Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Conditions: CD27 Expressing B-cell Malignancies;   CD27 Expressing Solid Tumors;   Chronic Lymphocytic Leukemia;   Burkett's Lymphoma;   Mantle Cell Lymphoma;   Primary Lymphoma of the Central Nervous System;   Marginal Zone B Cell Lymphoma;   Solid Tumor;   Metastatic Melanoma;   Renal (Clear) Cell Carcinoma;   Hormone-refractory Prostate Adenocarcinoma;   Ovarian Cancer;   Colorectal Adenocarcinoma;   Non-small Cell Lung Cancer;   Melanoma (Solid Tumor Expansion Arm Only)
Intervention: Drug: CDX-1127
3 Unknown † Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gastric Cancer;   Liver Cancer;   Melanoma (Skin);   Metastatic Cancer;   Ovarian Cancer;   Pancreatic Cancer
Interventions: Drug: cyclophosphamide;   Drug: poly ICLC;   Procedure: hepatic artery embolization;   Radiation: 3-dimensional conformal radiation therapy
4 Recruiting A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions: Drug: Fluderabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Biological: Aldesleukin
5 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
6 Recruiting Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer;   Pancreatic Cancer;   Periampullary Adenocarcinoma;   Small Intestine Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: oxaliplatin;   Other: laboratory biomarker analysis
7 Recruiting Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Conditions: Neuroendocrine Neoplasms;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
Intervention:
8 Recruiting A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Conditions: Neoplasms;   Neoplasms, Ovarian;   Neoplasms, Breast
Interventions: Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB;   Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
9 Unknown † Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Cervical Cancer;   Endometrial Cancer;   Esophageal Cancer;   Fallopian Tube Cancer;   Gastric Cancer;   Ovarian Cancer;   Sarcoma;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: informational intervention;   Procedure: assessment of therapy complications;   Procedure: psychosocial assessment and care
10 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8
11 Recruiting Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Melanoma;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Biological: recombinant interleukin-15;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Recruiting Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Conditions: Gastrointestinal Neoplasms;   Cancer of Gastrointestinal Tract;   Cancer of the Gastrointestinal Tract;   Gastrointestinal Cancer;   Neoplasms, Gastrointestinal
Intervention:
13 Recruiting Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Conditions: Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
Interventions: Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
14 Recruiting Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
15 Recruiting A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Conditions: Breast Cancer;   Lung Cancer;   Renal Cancer;   Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
16 Recruiting Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Lung Cancer;   Melanoma (Skin);   Pancreatic Cancer
Intervention:
17 Recruiting Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Conditions: Adenocarcinoma of the Lung;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Squamous Cell Lung Cancer;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Colon Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer
Interventions: Other: educational intervention;   Other: medical chart review
18 Not yet recruiting Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Procedure: disease screening;   Procedure: evaluation of cancer risk factors;   Procedure: genitourinary surgical procedure;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
19 Recruiting A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Conditions: Neoplasms;   Neoplasm Metastasis;   Pancreatic Cancer
Interventions: Drug: LY2157299;   Drug: Gemcitabine;   Drug: Placebo
20 Recruiting Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
Conditions: Lung Cancer;   Non Small Cell Lung Cancer (NSCLC);   Breast Cancer;   ER+ Breast Cancer
Interventions: Drug: entinostat;   Drug: Erlotinib;   Drug: Exemestane
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years